The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.
SBC: TRANSGENOMIC, INC. Topic: 103
DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Neuralexo, LLC Topic: 106
Abstract Stroke is a leading cause of morbidity and mortality in the United States However less than of patients are eligible for the current approved interventions of tissue plasminogen activator or thrombectomy We seek to develop new therapeutics to reduce the extent of damage and functional impairment resulting from ischemic injury to the brain an area of significant unmet medical need ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health